Gilead Sciences announced a significant milestone: the U.S. FDA accepted their New Drug Applications (NDAs) for lenacapavir ...

A new study in the journal Human Gene Therapy indicates that DNA impurities derived from plasmid and host cell DNA are ...

AI-assisted adeno-associated virus (AAV) capsid engineering has transformative potential in terms of accelerating and optimizing the development of gene therapies. That’s the view of Fangzhi Tan ...

The Zika virus builds tiny tunnels, called tunneling nanotubes, to stealthily transport material needed to infect nearby ...

Regenxbio is ranked Strong Buy due to low EV, strong partnerships, royalty income, bullish trends, and buyout potential.

SineuGene Therapeutics receives US FDA’s investigational new drug application clearance for SNUG01 to treat amyotrophic lateral sclerosis: Beijing Thursday, March 27, 2025, 15:0 ...

For many years, scientists have explored the structural changes of the virus capsid which encases the genome. In contrast, much less is known about the virus matrix—the outer protein shell ...

The firm said this view is based on encouraging efficacy to date, the use of a different adeno-associated virus capsid and transgene versus Elevidys, and a clean safety profile to date, with no ...

A combination of imaging techniques reveals how herpes simplex virus type 1 assembles within infected cells, highlighting the roles of essential viral proteins in viral assembly and exit.

Two oral presentations will highlight the continued potent antiviral activity of ALG-000184 for chronic hepatitis B virus (HBV) infection in both HBeAg-positive and HBeAg-negative subjects, ...

Neutralising antibodies can prevent severe courses Infections with the hepatitis E virus often go unnoticed because they cause no symptoms. However, in patients with weakened immune system or existing ...